These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 21138381)

  • 1. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration.
    Swan D; Long J; Carr O; Flanagan J; Irish H; Keating S; Keaveney M; Lambert J; McCormick PA; McKiernan S; Moloney J; Perry N; Cullen W
    AIDS Patient Care STDS; 2010 Dec; 24(12):753-62. PubMed ID: 21138381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals.
    Treloar C; Newland J; Rance J; Hopwood M
    J Viral Hepat; 2010 Dec; 17(12):839-44. PubMed ID: 20070504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.
    Cullen W; Stanley J; Langton D; Kelly Y; Bury G
    Eur J Gen Pract; 2007; 13(1):5-12. PubMed ID: 17366287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection.
    Grebely J; Genoway K; Khara M; Duncan F; Viljoen M; Elliott D; Raffa JD; DeVlaming S; Conway B
    Int J Drug Policy; 2007 Oct; 18(5):437-43. PubMed ID: 17854734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia.
    Doab A; Treloar C; Dore GJ
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S313-20. PubMed ID: 15768340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Where are people being tested for anti-HCV in England? Results from sentinel laboratory surveillance.
    Brant LJ; Hurrelle M; Balogun MA; Klapper P; Ramsay ME;
    J Viral Hepat; 2008 Oct; 15(10):729-39. PubMed ID: 18637078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
    Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
    BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada.
    Myles A; Mugford GJ; Zhao J; Krahn M; Wang PP
    Can J Gastroenterol; 2011 Mar; 25(3):135-9. PubMed ID: 21499577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
    Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
    BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access to treatment for Hepatitis C among injection drug users: results from the cross-sectional HOPE IV study.
    Souliotis K; Agapidaki E; Papageorgiou M; Voudouri N; Contiades X
    Int J Equity Health; 2017 Jun; 16(1):101. PubMed ID: 28615023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of HCV and HIV infections among people who inject drugs.
    Grebely J; Tyndall MW
    Curr Opin HIV AIDS; 2011 Nov; 6(6):501-7. PubMed ID: 22001894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "It gives me a sense of belonging": providing integrated health care and treatment to people with HCV engaged in a psycho-educational support group.
    Woolhouse S; Cooper E; Pickard A
    Int J Drug Policy; 2013 Nov; 24(6):550-7. PubMed ID: 23860471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience of hepatitis C testing among injecting drug users in Sydney, Australia.
    Day CA; White B; Thein HH; Doab A; Dore GJ; Bates A; Holden J; Maher L
    AIDS Care; 2008 Jan; 20(1):116-23. PubMed ID: 18278622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia.
    Treloar C; Rance J; Bath N; Everingham H; Micallef M; Day C; Hazelwood S; Grebely J; Dore GJ
    Int J Drug Policy; 2015 Oct; 26(10):992-8. PubMed ID: 25697089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoting equitable access to hepatitis C treatment for Indo-Chinese injecting drug users.
    Coupland H; Day C; Levy MT; Maher L
    Health Promot J Austr; 2009 Dec; 20(3):234-40. PubMed ID: 19951245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examination of the risk of reinfection with hepatitis C among injecting drug users who have been tested in Glasgow.
    McDonald SA; Hutchinson SJ; Cameron SO; Innes HA; McLeod A; Goldberg DJ
    Int J Drug Policy; 2012 Sep; 23(5):353-7. PubMed ID: 22421553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a general practice based hepatitis C virus screening intervention.
    Anderson EM; Mandeville RP; Hutchinson SJ; Cameron SO; Mills PR; Fox R; Ahmed S; Taylor A; Spence E; Goldberg DJ
    Scott Med J; 2009 Aug; 54(3):3-7. PubMed ID: 19728405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The common sense model applied to hepatitis C: a qualitative analysis of the impact of disease comparison and witnessed death on hepatitis C illness perception.
    Safo SA; Batchelder A; Peyser D; Litwin AH
    Harm Reduct J; 2015 Jun; 12():20. PubMed ID: 26092261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of injecting drug use status on hepatitis C-related referral and treatment.
    Stoové MA; Gifford SM; Dore GJ
    Drug Alcohol Depend; 2005 Jan; 77(1):81-6. PubMed ID: 15607844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.